[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.134.98. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
January 2019

Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis

Author Affiliations
  • 1Department of Dermatology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania
JAMA Dermatol. 2019;155(1):121-122. doi:10.1001/jamadermatol.2018.3906

Prurigo nodularis (PN) is a common and debilitating condition with no treatments approved by the US Food and Drug Administration. Herein, we describe cases of PN effectively treated with dupilumab (Dupixent; Regeneron-Sanofi).

Four patients with chronic, treatment-resistant PN presented with classic PN clinical findings without any clinical evidence of atopy. Three of the 4 patients had biopsies to confirm the PN nodules. Treatment with mirtazapine, 15 mg nightly, superpotent topical steroid ointments, and topical calcineurin inhibitor ointments had failed in all 4 cases. All patients reported no change with sun exposure. Two of the 4 patients had undergone narrowband UV-B therapy without improvement.

×